<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Tushar Jain on Medium]]></title>
        <description><![CDATA[Stories by Tushar Jain on Medium]]></description>
        <link>https://medium.com/@tushar-jain?source=rss-4b1c4f8eaa26------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*l9PwHnGOhMbkj1Sm</url>
            <title>Stories by Tushar Jain on Medium</title>
            <link>https://medium.com/@tushar-jain?source=rss-4b1c4f8eaa26------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 19:54:06 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@tushar-jain/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Agentic AI in Clinical Trial Operations]]></title>
            <link>https://medium.com/@tushar-jain/agentic-ai-in-clinical-trial-operations-4c197676b11d?source=rss-4b1c4f8eaa26------2</link>
            <guid isPermaLink="false">https://medium.com/p/4c197676b11d</guid>
            <category><![CDATA[clinical-drug-development]]></category>
            <category><![CDATA[clinical-operations]]></category>
            <category><![CDATA[agentic-ai]]></category>
            <category><![CDATA[ai-agent]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Tushar Jain]]></dc:creator>
            <pubDate>Fri, 29 May 2026 02:53:59 GMT</pubDate>
            <atom:updated>2026-05-29T02:53:59.764Z</atom:updated>
            <content:encoded><![CDATA[<p><em>A Strategic Perspective on Cognition, Agentic Paradox, Token Economics, and Validation</em></p><h3>Executive Summary</h3><p>Clinical trial operations have entered a new architectural and business phase in 2026. For two decades, clin-ops software has been anchored in Systems of Record such as EDC, CTMS, eTMF, IRT, RTSM, and Safety/PV platforms etc. that hold canonical data, validated workflows, and audit trails. Agentic AI introduces a cognition layer above those systems.</p><p>The strategic question is no longer only who owns the record, but who can reason across records, validate that reasoning, and expose the cost levers that make it scalable. This cognition layer would directly impact whether clinical research team members continue to suffer from systemic portal fatigue — toggling between disparate, siloed platforms to resolve a single data query — or whether trial operations can achieve the lower-friction execution needed to improve cycle times and help compress clinical trial timelines.</p><p>By mid-2026 four developments have converged far enough that biopharma, medtech, and CRO leaders should treat agentic AI in clinical operations as an architectural decision, not only as a pilot decision for the business case.</p><ol><li>Clin-Ops software may be separating into three layers: custody, cognition, and governance.</li><li>The Agentic Paradox — probabilistic AI meeting deterministic GxP oversight — is becoming architecturally addressable in bounded, validated use cases. Regulatory principles and risk-based validation thinking have firmed up.1,2 Open standards for connecting agents to enterprise systems have moved toward neutral governance.3,4</li><li>Token economics are not just a procurement issue. Model provider selection, pricing strategy, routing, caching, batching, and replay may further determine the long-run cost curve.</li><li>Recorded, replayable traces could become the technical mechanism that turns repeated agentic work into validated software behavior.</li></ol><p>The practical implication is that sponsors should begin making architectural decisions that will determine whether production use is possible at scale: which systems retain custody, which layer performs cognition, who owns the governance/control plane, how agent behavior is recorded and replayed, which validation package governs it, and which cost levers are visible to the buyer.</p><h3>1. A Cognitive Layer Is Appearing Above Custody of Data</h3><p>For most of the past two decades, the strategic question in clinical trial software has been about Systems of Record — who holds the canonical version of the data, the validated workflow state, and the audit trail. Veeva, Medidata, Oracle Life Sciences, and IQVIA built durable positions by being systems of record for trial data, regulatory documents, safety reporting, site management, and adjacent clinical applications.7,8,9,10</p><p>In this paper, custody means control of canonical data, workflow state, audit trail, and the validated system boundary. Cognition means the reasoning and orchestration layer that reads from, writes to, and coordinates across those systems. Custody in this sense is technical — control of these artifacts — not legal ownership of the data or accountability for the trial; under the quality system, the sponsor retains regulatory accountability across all three stacks regardless of who holds the record or performs the cognition.</p><p>A growing cohort of specialist agentic vendors has taken a different position. Companies such as Medable, Evinova, Saama, Owkin, Castor, and Dataiku position their products around cross-system reasoning, decentralized-trial workflows, and operational automation, and generally sit above the Systems of Record rather than holding custody of the canonical trial dataset themselves.11,12,13</p><p>a16z has described the broader enterprise-software shift as a move from System of Record to System of Intelligence.14 In clinical development, the analogous question is whether the new cognition layer will be controlled by the same vendor that holds custody, or by a separate layer above records. A second question now becomes equally important: who owns the governance/control plane between agent intent and regulated execution? The governance layer means the rules, approvals, identity checks, policy constraints, execution gates, trace logging, and audit evidence every agent action must pass through before it touches a regulated workflow.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*uC5fMcxD4aFlgK1IsZRH5w.png" /><figcaption><em>Figure 1. Three strategic stacks for agentic AI in clinical operations. Each stack places Data Custody, Cognition, and Governance ownership in different hands.</em></figcaption></figure><p>Anthropic’s Model Context Protocol (MCP) and Google’s Agent2Agent (A2A) protocol provide early open substrates for connecting agents to systems and to one another.3,4 The protocols do not by themselves solve identity, authorization, validation, data residency, vendor-commercial barriers, or governance ownership. In a clinical setting these gaps are consequential: agents that read and write across systems touch protected health information and trial-subject data, so site- and user-level identity, role-based access and least privilege, model-provider data-retention terms, cross-border data residency, resistance to prompt injection and tool poisoning in connected-agent workflows, and an audit trail of failed, blocked, and partially executed actions are all part of the governance problem rather than properties that open integration protocols supply on their own. But they make cross-System-of-Record cognition technically more plausible than bespoke integrations alone.</p><p>Each major incumbent has now announced its own agent layer — including Veeva AI Agents, Oracle Life Sciences AI Data Platform, Medidata Dot, and IQVIA.ai.7,8,9,10 The key question is whether these become genuine cognition layers that can reason broadly across enterprise clinical data, or remain extensions of the custody perimeter. Public adoption of MCP or A2A as first-class integration targets would be one observable signal either way. It is equally possible that incumbents succeed in folding cognition back into custody, in which case the separation described here would be partial and the pull toward incumbent stacks correspondingly strong; how far the layers ultimately separate is still an open question rather than a settled trend.</p><p>This pattern matters because the procurement decision is structural before it is contractual. The choice of stack dictates whether an organization aligns its deployment with an incumbent’s roadmap, separates specialist cognition from custody, or takes full internal ownership of the orchestration and governance architecture. The deeper question is who controls the layer that approves, blocks, logs, validates, and replays agent actions across those configurations.</p><h3>2. The Agentic Paradox Is Becoming Architecturally Addressable</h3><p>The defining tension in agentic AI for clinical operations is familiar. Large language models (LLMs) are probabilistic: they reason and adapt, but they do not guarantee identical outputs for identical inputs. GxP-regulated environments are designed around deterministic, auditable, reproducible behavior. This tension represents the Agentic Paradox.</p><p>The paradox is not solved in the abstract. It is becoming architecturally addressable in bounded, validated use cases. Two scaffoldings — one regulatory and one technical — have strengthened in roughly the same 18-month window.</p><p>On the technical side, open agent-integration protocols and emerging recorded-replay approaches provide a path to constrain, log, replay, and validate certain classes of agent behavior.3,4,6</p><p>On the regulatory side, ICH E6(R3) and the joint FDA-EMA principles for Good AI Practice in drug development point toward risk-based quality management, data governance, validation proportionality, metadata, audit trails, and human accountability; the FDA’s risk-based Computer Software Assurance approach, though framed for device production and quality systems rather than clinical trial conduct, reflects the same shift in validation thinking.1,2,15</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*2T2D-kp9W2oH1ZO9bYkw3A.png" /><figcaption><em>Figure 2. Technical and Regulatory scaffoldings have firmed up in the same window, making Agentic Paradox architecturally addressable</em></figcaption></figure><p>The important qualification is scope. A novel protocol-design recommendation or clinical safety interpretation is not an obvious replay candidate. Conversely, a recurring eTMF document-classification workflow, a standard clinical query-triage pattern, or structured data-quality checks are highly suitable. In these bounded settings, the question shifts from whether agentic AI can ever be validated to which workflows can be bounded, traced, replayed, risk-assessed, and governed under existing clinical quality systems.</p><h3>3. Token Economics Are an Architectural Lever, Not Just a Price Line</h3><p>Most operating plans treat token costs as a static procurement line item, focused on negotiated volume discounts. This framing tends to miss where the real leverage sits. Because the underlying model vendors have largely finalized their own architectural options, a biopharma buyer has limited ability to change a provider’s underlying cost structure. Much of the buyer’s economic leverage therefore comes through vendor and stack selection.</p><p>The choice of vendor and stack — A, B, or C — is largely what shapes a buyer’s access to six distinct token levers.</p><h3>Three strategic stacks for biopharma sponsors</h3><p>Before analyzing the specific levers, the buyer must evaluate the three foundational macro-architectures available for deploying agentic AI. These are not a separate framework from the custody, cognition, and governance layers introduced earlier; they are three ways of deciding who owns each of those layers. In all three scenarios, the operational end-user interacts with a single, unified agent interface. The critical choice depends on who owns that central engine, its current market maturity, and where the validation boundary sits.</p><p>• <strong>Stack A — Incumbent-owned intelligence.</strong> The sponsor aligns with a dominant System-of-Record vendor’s agent roadmap. The advantage is native optimization inside the vendor’s home custody boundary; the risk is roadmap dependency and asymmetric reach outside it. When orchestration crosses into another vendor’s SoR, the agent pays a selective interface tax through external APIs, request limits, and schema changes controlled by others. Governance / GxP validation typically sits with the SoR vendor, with sponsor QA oversight, and cost levers remain mostly inside the vendor stack.</p><p>• <strong>Stack B — Specialist cognition above existing Systems of Record.</strong> Specialists often position themselves as cross-vendor neutral because their product surface depends on reasoning symmetrically across multiple SoRs rather than extending one custody vendor’s perimeter. This may be the most viable near-term path where specialist frameworks are commercially mature. The tradeoff is that specialists still face write-sovereignty constraints: every transaction must pass through incumbent security and API gates, creating a universal interface tax and upstream API/schema drift risk. Governance / GxP validation responsibility is shared through the specialist’s quality system and the sponsor’s QA process, while cost visibility depends on contract and implementation design.</p><p><strong>• Stack C — Sponsor-governed orchestration through open protocols.</strong> The sponsor, often with a systems integrator (SI), owns the unified agent interface and governance/control plane using protocols such as MCP and A2A. This maximizes transparency over model selection, routing, batching, trace retention, and replay, and gives the buyer the best chance of capturing optimization savings directly. The tradeoff is a steep validation and maintenance burden: by owning the central engine, the sponsor takes on software-vendor-like obligations to maintain, revalidate, and defend a GxP control plane against continuous multi-vendor API drift and schema change.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*y3g4iThpXFELd52SYyIbFA.png" /><figcaption><em>Figure 3. Operating tradeoffs across the same three strategic stacks. Ratings are directional and depend on whether a workflow runs inside a vendor’s native boundary or across vendors, and on the specific contract and validation terms.</em></figcaption></figure><h3>The Six Token Architectural Levers Determined by Vendor Selection</h3><p>When a buyer selects a vendor within one of the stacks above, they are fundamentally making a downstream decision across six structural axes:</p><p><strong>1. Pricing Strategy: </strong>The choice of vendor dictates how token consumption is commercialized. In Stack A, incumbents naturally default to a Bundled Study-Level or Outcome-Based pricing model. This completely hides the underlying token consumption, aligning payment with clinical value but preventing the buyer from capturing optimization savings. Conversely, Stack C forces a raw API Pass-Through model, while Stack B typically features a Hybrid/Tiered Strategy where token cost transparency varies heavily by contract and implementation.</p><p><strong>2. Model Selection:</strong> By selecting a vendor stack, the pharma buyer determines their level of access to — and control over — the underlying model tiers. In the current market, these are stratified into three distinct operational classes based on cost and reasoning depth:</p><p>● Frontier Tier (Premium Reasoning): Premium engines like OpenAI GPT-5.5 and Claude Opus 4.7, commanding the top price point of $5.00 per 1M input tokens. These high-compute models are reserved strictly for novel, judgment-heavy clinical tasks such as protocol strategy formulation or complex safety and serious adverse event (SAE) interpretations.</p><p>● Mid-Tier (Balanced Orchestration): Efficiency-optimized models like Gemini 3.5 Flash, priced at $1.50 per 1M input tokens. This tier serves as the operational workhorse for semi-structured tasks that require high-throughput tool calling, cross-system context handling, and automated draft query generation.</p><p>● Lightweight Tier (High-Volume Utility): Hyper-scaled utility models such as Gemini 3.1 Flash-Lite, anchoring the low end of the cost curve at $0.25 per 1M input tokens. These models are optimized for high-volume, stable, rules-like workflows such as standard eTMF document classification or recurring metadata integrity checks.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*m419NFa6Zv4DRg9Jh83yrQ.png" /><figcaption><em>Figure 4. Latest 2026 Token input/output prices by LLM models showing a roughly 20x spread across representative model lineups.</em>5<em> This is a representative posted input-price spread, not a guaranteed end-to-end clinical-workflow cost; effective cost also depends on output and reasoning tokens, cache-hit rates, tool calls, and batch eligibility.</em></figcaption></figure><p>The strategic impact of the stack decision is significant: in both Stack A and Stack B, model selection sits largely with the vendor, shaped by their existing enterprise partnerships with specific model providers. Stack C, by contrast, gives the buyer broad flexibility to swap and integrate models directly at the orchestration level.</p><p>Also, it is important to understand the cost structure of Model Providers such as Google, Anthropic, OpenAI, and xAI for long-term planning. A provider that owns more of the stack — data centers, accelerators, power procurement, networking, or specialized inference infrastructure — may have a lower structural cost base than one renting more layers from others.16,17 That helps explain why published model prices differ. For clinical buyers, the practical question is simpler: does the vendor expose enough control of model routing, caching, batching, and replay to let the biopharma buyer benefit from those economics?</p><p><strong>3. Model Routing:</strong> Model routing dynamically matches a clinical task to the cheapest model capable of executing it. Running an unconstrained frontier model against simple tasks like eTMF metadata tagging is needlessly expensive. Choosing Stack C allows the buyer to enforce custom routing policies that triage routine data checks to low-cost models, reserving expensive frontier engines strictly for complex protocol exceptions. In Stack A and Stack B, routing logic is entirely managed under the vendor’s control.</p><p><strong>4. Prompt Caching:</strong> Clinical trial operations are dominated by massive, highly repetitive document contexts — such as 150-page clinical protocols, Investigator Brochures (IBs), and dense regulatory guidance documents. Prompt Caching could dramatically slash input token costs by retaining these static contexts through provider-side prompt caching across sequential queries. If a buyer selects a Stack A vendor, the financial gains of prompt caching are captured as pure margin by the vendor. In Stack C (and transparently negotiated Stack B implementations), the buyer directly captures these prompt cost reductions.</p><p><strong>5. Batch Processing: </strong>Not all clinical operations require real-time, zero-latency execution. Massive document reconciliations, historical eTMF audits, and site query trends can run asynchronously. Standard model APIs offer steep discounts (frequently up to 50%) for workloads executed via Batch Processing queues within a 24-hour window. Buyers selecting Stack C can build native asynchronous processing queues to exploit these economics systematically, while Stack A and B users are bound to the real-time or batch infrastructure pre-selected by the vendor.</p><p><strong>6. Recorded Replay:</strong> Recorded Replay represents a critical token optimization lever: it could eliminate language model invocation entirely for stable, repeated workflows where an execution trace remains valid. By replaying a verified technical trace rather than re-generating an LLM call, the model-invocation cost for that transaction drops to zero. By selecting a vendor, the buyer determines whether the system’s architecture supports trace versioning, automated revalidation triggers, and fallback exceptions required to run replay safely within a GxP environment.</p><h3>How the cost levers compound</h3><p>Within a given provider lineup, several choices can stack. Model routing sends each task to the cheapest model capable of handling it. Prompt caching can reduce the cost of repeated input. Batch processing can reduce the cost of work that does not need to run in real time. Recorded replay can reduce or eliminate LLM calls for stable, repeated workflows where the trace remains valid.18,6</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4wjvvVbHeXwCzo0krI7HJA.png" /><figcaption><em>Figure 5. The cumulative cost effect of routing, caching, batching, and replay is illustrative; the pattern matters more than the exact numbers.</em></figcaption></figure><p>Two organizations can both choose Stack A and still land in different places: one may use hybrid routing, caching, batching, and replay under an outcome-based contract; another may run premium models against every task under a token pass-through model. The difference lies in which of the six levers each is able to use.</p><p>And this is why outcome-based or study-level pricing deserves careful scrutiny. It can be attractive because it aligns payment with value, but it can also conceal whether the vendor is capturing the gains from routing, caching, batching, and replay. Sponsors should ask which levers are visible, which are contractually controlled, and which remain inside the vendor’s margin model.</p><h3>4. Recorded Replay Closes the Loop Between Validation and Cost</h3><p>The two threads developed above meet in a single mechanism. The validation challenge of Section 2 and the cost levers of Section 3 converge on recorded replay: an emerging technique for making probabilistic agent behavior reproducible enough to govern, while at the same time flattening the long-run cost curve by bypassing repeated LLM invocations. The underlying idea is not new. Deterministic record-and-replay has been an established approach in software engineering for years, capturing a nondeterministic execution once — its prompt context, model version, tool calls, decision points, and human-review events — so it can be reproduced exactly on demand.19 What is new — and still early — is its application to agentic AI in regulated clinical workflows, where the published evidence base is only beginning to form.6</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*df8GOObtytF_jF-npwm9fQ.png" /><figcaption><em>Figure 6. Recorded Replay — First execution records the trace; later executions replay it where the trace remains valid.</em></figcaption></figure><p>Replay suitability is workflow-specific:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*HB1GzC9KzbuZ8Ca9XaIfTg.png" /></figure><p>The qualifications are material. Recorded traces depend on stable inputs, schemas, tools, model versions, and policy rules. Protocol amendments, schema migrations, upstream API changes, new model versions, or new risk controls may invalidate a recording and require revalidation. A production implementation therefore needs automated schema and drift checks, trace versioning and invalidation triggers, and immediate fallback to human-in-the-loop (HITL) review when a policy, schema, or confidence threshold is breached. Naively implemented replay can fail silently, so the fail-closed path is not optional.</p><p>Within those limits, replay reframes both conversations at once. On the validation side, instead of trying to validate an unconstrained stochastic system, the sponsor validates bounded workflow classes, execution traces, revalidation triggers, and fallback exceptions. Importantly, replay reproduces the execution path, not the semantic correctness of a genuinely new case: a replayed eTMF classification flow can still mishandle a document type it has not seen, which is why drift detection and the fallback to human review do the real work when inputs move outside the validated distribution. On the cost side, the same trace that makes a workflow auditable also removes its largest recurring expense, the model call itself. A single mechanism can therefore serve both the governance case and the economic one.</p><h3><strong>Conclusion</strong></h3><p>The four patterns outlined in this paper do not exist in isolation; together they point to a single place where the threads meet. Recorded replay is emerging as the technical convergence point where validation viability and operational economics could come together.</p><p>Crucially, these architectural abstractions carry profound human consequences at the site level. For clinical operations executives, solving the custody-versus-cognition split is the key to eliminating the portal and site fatigue that plagues clinical trials. By engineering a unified cognitive layer that seamlessly orchestrates across siloed Systems of Record, biopharma sponsors can reduce coordinator burnout, eliminate manual data transcription errors, and materially accelerate the path to database lock.</p><p>The organizations that answer these architectural questions before vendor frameworks fully harden will capture immense strategic optionality and return on investment (ROI). They will be uniquely positioned to objectively audit the three strategic stacks — incumbent-owned intelligence, specialist cognition, and sponsor-governed orchestration — evaluating them not on marketing promises, but on system reach, auditability, validation overhead, cost transparency, and long-term contract lock-in.</p><h3>References</h3><p>1. FDA, Computer Software Assurance for Production and Quality System Software, final guidance, September 24, 2025; updated February 3, 2026.</p><p>2. FDA, ICH E6(R3) Good Clinical Practice, final guidance, September 8, 2025. ICH E6(R3) Principles and Annex 1 adopted January 6, 2025; EMA effective July 23, 2025.</p><p>3. Anthropic, Introducing Model Context Protocol, November 25, 2024. <a href="https://www.anthropic.com/news/model-context-protocol">https://www.anthropic.com/news/model-context-protocol</a></p><p>4. Google Developers Blog, Announcing the Agent2Agent Protocol (A2A), April 9, 2025; Linux Foundation, Agent2Agent (A2A) project launch, June 23, 2025.</p><p>5. OpenAI, API Pricing, <a href="https://openai.com/api/pricing/;">https://openai.com/api/pricing/;</a> Anthropic, Claude API pricing, <a href="https://platform.claude.com/docs/en/about-claude/pricing;">https://platform.claude.com/docs/en/about-claude/pricing;</a> Google AI for Developers, Gemini Developer API pricing, <a href="https://ai.google.dev/gemini-api/docs/pricing.">https://ai.google.dev/gemini-api/docs/pricing.</a> May 2026 snapshot; accessed May 27, 2026.</p><p>6. Wang, X.; Yu, K.; Liang, X.; Wang, L.; Han, C. Good to Go: The LOOP Skill Engine That Hits 99% Success and Slashes Token Usage by 99% via One-Shot Recording and Deterministic Replay. arXiv:2605.14237, May 14, 2026. <a href="https://arxiv.org/abs/2605.14237">https://arxiv.org/abs/2605.14237</a></p><p>7. Veeva Systems, Veeva AI Agents announcement, October 14, 2025.</p><p>8. Medidata (Dassault Systemes), Luminary rating from Everest Group 2026 Innovation Watch, March 3, 2026.</p><p>9. Oracle, Oracle Life Sciences AI Data Platform, January 29, 2026. <a href="https://www.oracle.com/news/announcement/oracle-life-sciences-ai-data-platform-unites-data-and-agentic-intelligence-2026-01-29/">https://www.oracle.com/news/announcement/oracle-life-sciences-ai-data-platform-unites-data-and-agentic-intelligence-2026-01-29/</a></p><p>10. IQVIA, IQVIA.ai launch at NVIDIA GTC, March 16, 2026.</p><p>11. Saama, Modular and Adaptive AI Agents for Clinical Innovation, September 29, 2025.</p><p>12. Owkin, K Pro launch, October 16, 2025; Pathology Explorer in Claude for Healthcare and Life Sciences, January 12, 2026.</p><p>13. General characterization based on these companies’ public product and platform communications, 2025–2026: Medable (decentralized-trial orchestration), Evinova (digital clinical trial platform), Dataiku (life-sciences AI agents), and Castor (clinical AI products).</p><p>14. a16z, From System of Record to System of Intelligence, Ahern, Zhang, Immerman, May 14, 2026. <a href="https://a16z.com/from-system-of-record-to-system-of-intelligence/">https://a16z.com/from-system-of-record-to-system-of-intelligence/</a></p><p>15. EMA and FDA, Guiding Principles of Good AI Practice in Drug Development, January 2026; joint announcement January 14, 2026. <a href="https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0">https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0</a></p><p>16. SemiAnalysis, TPUv7: Google Takes a Swing at the King, November 2025.</p><p>17. VentureBeat, How Google’s TPUs are reshaping the economics of large-scale AI, December 22, 2025. <a href="https://venturebeat.com/ai/how-googles-tpus-are-reshaping-the-economics-of-large-scale-ai">https://venturebeat.com/ai/how-googles-tpus-are-reshaping-the-economics-of-large-scale-ai</a></p><p>18. Anthropic API documentation on prompt caching and Message Batches; OpenAI documentation on prompt caching and Batch API; Google Gemini documentation on context caching, batch mode, and pricing, May 2026 snapshot.</p><p>19. O’Callahan, R.; Jones, C.; Froyd, N.; Huey, K.; Noll, A.; Partush, N. Engineering Record and Replay for Deployability. Proceedings of the USENIX Annual Technical Conference (ATC), 2017. <a href="https://www.usenix.org/conference/atc17/technical-sessions/presentation/ocallahan">https://www.usenix.org/conference/atc17/technical-sessions/presentation/ocallahan</a></p><h3>About the Author</h3><p>Tushar Jain works in strategy consulting in the life sciences sector. All his views are his own and not of any employer. He can be reached on <a href="https://www.linkedin.com/in/jtushar/">LinkedIn</a>.</p><p><a href="https://dl.orangedox.com/sVYTSQjOcujCKS2avx"><strong>Download the full PDF here</strong></a><strong>.</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4c197676b11d" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>